AGREEMENT AND PLAN OF MERGER by and among: DOVA PHARMACEUTICALS, INC., SWEDISH ORPHAN BIOVITRUM AB (PUBL) and DRAGONFLY ACQUISITION CORP. September 30, 2019Agreement and Plan of Merger • October 3rd, 2019 • Dova Pharmaceuticals Inc. • Pharmaceutical preparations • Delaware
THIS AGREEMENT AND PLAN OF MERGER (“Agreement”) is made and entered into as of September 30, 2019 (the “Agreement Date”), by and among: Swedish Orphan Biovitrum AB (publ), a Swedish public limited liability company (“Parent”); Dragonfly Acquisition Corp., a Delaware corporation and an indirect wholly owned Subsidiary of Parent (“Purchaser”); and Dova Pharmaceuticals, Inc., a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement shall have the meanings ascribed to such terms in Section 1.
